Literature DB >> 16499260

Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia.

D J Jeffries1, P C Hill, A Fox, M Lugos, D J Jackson-Sillah, R A Adegbola, R H Brookes.   

Abstract

SETTING: An urban area, The Gambia.
OBJECTIVE: To identify ELISPOT and PPD skin test cut-offs, targeting sensitivity and specificity equivalence.
DESIGN: Tuberculosis cases >5 years of age and their household contacts underwent ELISPOT, HIV and PPD skin tests. Cases and contacts sleeping in a different house were used to estimate sensitivity and specificity, providing two planes for estimating cut-offs. Specificity was adjusted for infection from previous exposure using a multivariate discrimination algorithm.
RESULTS: The point on the line of intersection of the planes that maximised sensitivity and specificity equivalence occurred at 4 spots (95% confidence interval [CI] 3.5-5, multiplier=0 ) for CFP-10 and 5.5 spots (4.5-8, multiplier=0 for ESAT-6), yielding a sensitivity and specificity of 76% for both antigens. Combining ESAT-6 and CFP-10 using an 'or' statement yielded a maximum equivalence sensitivity and specificity of 76.5% at 6 spots for ESAT-6 and 11.5 spots for CFP-10. For the PPD skin test sensitivity and specificity, an equivalence of 78% occurred at 11 mm induration (9-13 mm).
CONCLUSION: An ELISPOT cut-off for ESAT-6 or CFP-10 could be set at 4-8 spot forming units (20-40 spots per million), with little benefit from combining the results. A cut-off of 9-13 mm for the PPD skin test is reasonable when comparing with the ELISPOT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16499260

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  11 in total

1.  Reproducibility of QuantiFERON-TB gold in-tube assay.

Authors:  Sharon Perry; Luz Sanchez; Shufang Yang; Zubin Agarwal; Philip Hurst; Julie Parsonnet
Journal:  Clin Vaccine Immunol       Date:  2008-01-16

2.  Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases.

Authors:  Ifedayo M O Adetifa; Martin O C Ota; Brigitte Walther; Abdulrahman S Hammond; Moses D Lugos; David J Jeffries; Simon A Donkor; Richard A Adegbola; Philip C Hill
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

3.  Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts.

Authors:  Philip C Hill; David J Jeffries; Roger H Brookes; Annette Fox; Dolly Jackson-Sillah; Moses D Lugos; Simon A Donkor; Bouke C de Jong; Tumani Corrah; Richard A Adegbola; Keith P McAdam
Journal:  PLoS One       Date:  2007-01-31       Impact factor: 3.240

4.  Infection with Helicobacter pylori is associated with protection against tuberculosis.

Authors:  Sharon Perry; Bouke C de Jong; Jay V Solnick; Maria de la Luz Sanchez; Shufang Yang; Philana Ling Lin; Lori M Hansen; Najeeha Talat; Philip C Hill; Rabia Hussain; Richard A Adegbola; Joanne Flynn; Don Canfield; Julie Parsonnet
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

5.  Immunogenicity of antigens from the TbD1 region present in M. africanum and missing from "modern" M. tuberculosis: a cross- sectional study.

Authors:  Bouke C de Jong; Abdulrahman Hammond; Jacob K Otu; Martin Antonio; Richard A Adegbola; Martin O Ota
Journal:  BMC Infect Dis       Date:  2010-01-19       Impact factor: 3.090

6.  Defining ELISpot cut-offs from unreplicated test and control wells.

Authors:  Neal Alexander; Annette Fox; Vu Thi Kim Lien; Tao Dong; Laurel Yong-Hwa Lee; Nguyen Le Khanh Hang; Le Quynh Mai; Peter Horby
Journal:  J Immunol Methods       Date:  2013-03-07       Impact factor: 2.303

7.  Stratified Threshold Values of QuantiFERON Assay for Diagnosing Tuberculosis Infection in Immunocompromised Populations.

Authors:  Haruyuki Ariga; Hideaki Nagai; Atsuyuki Kurashima; Yoshihiko Hoshino; Syunsuke Shoji; Yutsuki Nakajima
Journal:  Tuberc Res Treat       Date:  2011-06-27

8.  Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection.

Authors:  Philip C Hill; Roger H Brookes; Annette Fox; Dolly Jackson-Sillah; David J Jeffries; Moses D Lugos; Simon A Donkor; Ifedayo M Adetifa; Bouke C de Jong; Alex M Aiken; Richard A Adegbola; Keith P McAdam
Journal:  PLoS Med       Date:  2007-06       Impact factor: 11.069

9.  Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia.

Authors:  Ifedayo M O Adetifa; Moses D Lugos; Abdulrahman Hammond; David Jeffries; Simon Donkor; Richard A Adegbola; Philip C Hill
Journal:  BMC Infect Dis       Date:  2007-10-25       Impact factor: 3.090

10.  Quantitative PCR evaluation of cellular immune responses in Kenyan children vaccinated with a candidate malaria vaccine.

Authors:  Jedidah Mwacharo; Susanna J Dunachie; Oscar Kai; Adrian V S Hill; Philip Bejon; Helen A Fletcher
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.